Clinical trial NCT06152575: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Official title: A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Multiple Myeloma
Keywords: Elranatamab
B-Cell Maturation Antigen
BCMA
Bispecific antibody
BCMA-CD3 bispecific antibody
Myeloma
Multiple myeloma
Relapsed multiple myeloma
Refractory multiple myeloma
MagnetisMM
MagnetisMM-32
Pomalidomide
Elotuzumab
Bortezomib
Carfilzomib
PF-06863135
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2023-11-30
Enrollment: 492
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).

This study is seeking participants who:

* Are 18 years of age or older and have MM.
* Have received treatments before for MM.
* Have MM that has returned or not responded to their most recent treatment.

Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM.

Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study.

The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as:

* a shot under the skin at the study clinic
* through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects.

Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits).

The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.


Eligibility criteria: Inclusion Criteria:

* Prior diagnosis of multiple myeloma as defined by International Myeloma Working Group (IMWG) criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide.
* Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria.
* Measurable disease defined as at least 1 of the following: (a) Serum M-protein ≥0.5 g/dL; (b) Urinary M-protein excretion ≥200 mg/24 hours; (c) Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (\<0.26 or \>1.65).
* Have clinical laboratory values within the specified range.
* ECOG (Eastern Cooperative Oncology Group) performance status ≤2.
* Not pregnant or breastfeeding and willing to use contraception.

Exclusion Criteria:

* Smoldering multiple myeloma.
* Plasma cell leukemia.
* Amyloidosis.
* Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities (POEMS) syndrome.
* Known central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement.
* Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease.
* Any active, uncontrolled bacterial, fungal, or viral infection.
* Any other active malignancy within 3 years prior to enrolment (exceptions include, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ)
* Previous treatment with a B cell maturation antigen (BCMA)-directed therapy or CD3-redirecting therapy.
* Unable to receive investigator's choice therapy.
* Live attenuated vaccine within 4 weeks of the first dose of study intervention.
* Administration with an investigational product (e.g. drug or vaccine) within 30 days preceding the first dose of study intervention used in this study.

Primary outcomes:
measure: Progression free survival per International Myeloma Working Group criteria
timeFrame: Up to approximately 5 years
Secondary outcomes:
measure: Overall survival
timeFrame: Up to approximately 5 years
measure: Progression free survival on next-line treatment per International Myeloma Working Group criteria
timeFrame: Up to approximately 5 years
measure: Objective response rate per International Myeloma Working Group criteria
timeFrame: Up to approximately 5 years
measure: Duration of response per International Myeloma Working Group criteria
timeFrame: Up to approximately 5 years
measure: Very good partial response or better response rate per International Myeloma Working Group criteria
timeFrame: Up to approximately 5 years
measure: Complete response rate per International Myeloma Working Group criteria
timeFrame: Up to approximately 5 years
measure: Duration of complete response per International Myeloma Working Group criteria
timeFrame: Up to approximately 5 years
measure: Time to response per International Myeloma Working Group criteria
timeFrame: Up to approximately 5 years
measure: Minimal residual disease negativity rate per International Myeloma Working Group criteria
timeFrame: Up to approximately 5 years
measure: Sustained minimal residual disease negativity rate per International Myeloma Working Group criteria
timeFrame: Up to approximately 5 years
measure: Duration of minimal residual disease negativity rate per International Myeloma Working Group criteria
timeFrame: Up to approximately 5 years
measure: Frequency of treatment-emergent adverse events
timeFrame: From date of first dose of study intervention up to 90 days after last study intervention administration
measure: Frequency of abnormal laboratory results
timeFrame: From date of first dose of study intervention up to 90 days after last study intervention administration
measure: Free elranatamab serum trough concentration [Ctrough]
timeFrame: From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab
measure: Elranatamab immunogenicity by anti-drug antibodies against elranatamab
timeFrame: From date of first dose of elranatamab up to approximately 14 days after last dose of elranatamab
measure: Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30
timeFrame: From date of informed consent up to approximately 35 days after last administration of study intervention
measure: Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20
timeFrame: From date of informed consent up to approximately 35 days after last administration of study intervention
Other outcomes:
Locations:
city: Mobile
country: United States
facility: Infirmary Cancer Care
state: Alabama
city: Beverly Hills
country: United States
facility: Beverly Hills Cancer Center
state: California
city: Clovis
country: United States
facility: Community Cancer Institute
state: California
city: Encino
country: United States
facility: Clinical Research Advisors (Encino Satellite Location)
state: California
city: Irvine
country: United States
facility: Hoag Health Center Irvine
state: California
city: Irvine
country: United States
facility: Hoag Hospital Irvine
state: California
city: Los Angeles
country: United States
facility: Clinical Research Advisors (Korea Town Satellite Location)
state: California
city: Los Angeles
country: United States
facility: Clinical Research Advisors (West Hollywood Satellite Location)
state: California
city: Newport Beach
country: United States
facility: Hoag Memorial Hospital Presbyterian
state: California
city: Sacramento
country: United States
facility: University of California Davis (UC Davis) Comprehensive Cancer Center
state: California
city: Sacramento
country: United States
facility: University of California
state: California
city: Fort Collins
country: United States
facility: UCHealth Harmony
state: Colorado
city: Longmont
country: United States
facility: Longs Peak Hospital
state: Colorado
city: Miami
country: United States
facility: Miami Cancer Institute at Baptist Health, Inc.
state: Florida
city: Plantation
country: United States
facility: BRCR Global
state: Florida
city: Tamarac
country: United States
facility: BRCR Global - Tamarac
state: Florida
city: Indianapolis
country: United States
facility: Community Health Network, Inc.
state: Indiana
city: Indianapolis
country: United States
facility: Community Health Network, Inc.
state: Indiana
city: Indianapolis
country: United States
facility: Community Health Network, Inc.
state: Indiana
city: Lincoln
country: United States
facility: Bryan Medical Center
state: Nebraska
city: Lincoln
country: United States
facility: NHO Revive Research Institute, LLC
state: Nebraska
city: Morristown
country: United States
facility: Atlantic Health System Morristown Medical Center
state: New Jersey
city: Hawthorne
country: United States
facility: WMCHealth Advanced Physician Services
state: New York
city: Ithaca
country: United States
facility: Cayuga Cancer Center at Cayuga Park
state: New York
city: Ithaca
country: United States
facility: Cayuga Medical Center
state: New York
city: Valhalla
country: United States
facility: Westchester Medical Center
state: New York
city: Greenville
country: United States
facility: Brody school of Medicine at East Carolina University
state: North Carolina
city: Greenville
country: United States
facility: ECU Health Medical Center
state: North Carolina
city: Cincinnati
country: United States
facility: Oncology Hematology Care Clinical Trials, LLC
state: Ohio
city: Cincinnati
country: United States
facility: TriHealth Cancer Institute-Good Samaritan Hospital
state: Ohio
city: Cincinnati
country: United States
facility: Oncology Hematology Care Clinical Trials, LLC
state: Ohio
city: Cincinnati
country: United States
facility: The Jewish Hospital
state: Ohio
city: Cincinnati
country: United States
facility: Oncology Hematology Care Clinical Trials, LLC
state: Ohio
city: Cincinnati
country: United States
facility: Oncology Hematology Care Clinical Trials, LLC
state: Ohio
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
city: Greenville
country: United States
facility: St Francis Cancer Center
state: South Carolina
city: Dallas
country: United States
facility: Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy
state: Texas
city: Dallas
country: United States
facility: Baylor University Medical Center
state: Texas
city: Houston
country: United States
facility: Houston Methodist Hospital
state: Texas
city: Houston
country: United States
facility: Houston Methodist Willowbrook Hospital
state: Texas
city: Irving
country: United States
facility: US Oncology Investigational Products Center (IPC)
state: Texas
city: Sugar Land
country: United States
facility: Houston Methodist Sugar Land Hospital
state: Texas
city: Temple
country: United States
facility: Baylor Scott & White Medical Center - Temple
state: Texas
city: Morgantown
country: United States
facility: WVU Cancer Institute
state: West Virginia
city: Madison
country: United States
facility: University of Wisconsin Carbone Cancer Center-University Hospital
state: Wisconsin
city: Madison
country: United States
facility: University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
state: Wisconsin
city: Ciudad Autónoma de Buenos Aires
country: Argentina
facility: Instituto Alexander Fleming
state: Buenos Aires
city: Pilar
country: Argentina
facility: Hospital Universitario Austral
state: Buenos Aires
city: Ciudad de Buenos Aires
country: Argentina
facility: Hospital Italiano de Buenos Aires
state: Ciudad Autónoma DE Buenos Aires
city: La Plata
country: Argentina
facility: Hospital Italiano de La Plata
city: Concord
country: Australia
facility: Concord Repatriation General Hospital
state: New South Wales
city: Birtinya
country: Australia
facility: Sunshine Coast University Hospital
state: Queensland
city: Fitzroy
country: Australia
facility: St Vincent's Hospital (Melbourne)
state: Victoria
city: Brussels
country: Belgium
facility: UZ Brussel
state: Bruxelles-capitale, Région DE
city: Gilly
country: Belgium
facility: Grand Hôpital de Charleroi
state: Hainaut
city: Hornu
country: Belgium
facility: Centre Hospitalier Epicura
state: Hainaut
city: Verviers
country: Belgium
facility: CHR Verviers - La Tourelle
state: Liège
city: Yvoir
country: Belgium
facility: Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi
state: Namur
city: Gent
country: Belgium
facility: UZ Gent
state: Oost-vlaanderen
city: Porto Alegre
country: Brazil
facility: Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
state: RIO Grande DO SUL
city: Porto Alegre
country: Brazil
facility: Centro de Pesquisa Clínica - Área Administrativa
state: RIO Grande DO SUL
city: Porto Alegre
country: Brazil
facility: Hospital Mae de Deus
state: RIO Grande DO SUL
city: Sao Paulo
country: Brazil
facility: Instituto D'Or de Pesquisa e Ensino (IDOR)
state: SÃO Paulo
city: SP
country: Brazil
facility: Clínica Médica São Germano LTDA
state: SÃO Paulo
city: Rio de Janeiro
country: Brazil
facility: Instituto de Educação, Pesquisa e Gestão em Saúde
city: Rio de Janeiro
country: Brazil
facility: Americas Centro de Oncologia Integrado
city: Rio de Janeiro
country: Brazil
facility: Instituto de Educação, Pesquisa e Gestão em Saúde
city: São Paulo
country: Brazil
facility: ESHO Empresa de Serviços Hospitalares S.A/ Hospital Samaritano de Higienópolis
city: São Paulo
country: Brazil
facility: Instituto D'Or de Pesquisa e Ensino (IDOR)
city: São Paulo
country: Brazil
facility: Hospital do Coracao
city: São Paulo
country: Brazil
facility: HU UNIFESP / SPDM - Hospital São Paulo
city: São Paulo
country: Brazil
facility: Universidade Federal de Sao Paulo
city: São Paulo
country: Brazil
facility: Clínica Médica São Germano S/S Ltda
city: Edmonton
country: Canada
facility: Cross Cancer Institute
state: Alberta
city: Moncton
country: Canada
facility: The Moncton Hospital
state: New Brunswick
city: Montreal
country: Canada
facility: Jewish General Hospital
state: Quebec
city: Montreal
country: Canada
facility: Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎ
state: Quebec
city: Brno
country: Czechia
facility: Fakultní nemocnice Brno Bohunice
state: Brno-město
city: Olomouc
country: Czechia
facility: Fakultni nemocnice Olomouc
state: Olomoucký KRAJ
city: Prague
country: Czechia
facility: Fakultni nemocnice Kralovske Vinohrady
state: Praha 10
city: Praha 2
country: Czechia
facility: Vseobecna fakultni nemocnice v Praze
city: Copenhagen
country: Denmark
facility: Rigshospitalet
state: Hovedstaden
city: Aarhus
country: Denmark
facility: Aarhus Universitetshospital, Skejby
state: Midtjylland
city: Aalborg
country: Denmark
facility: Aalborg Universitetshospital, Syd
state: Nordjylland
city: Tampere
country: Finland
facility: Tampereen yliopistollinen sairaala
state: Pirkanmaa
city: Oulu
country: Finland
facility: Oulun yliopistollinen sairaala
state: Pohjois-pohjanmaa
city: Kuopio
country: Finland
facility: Kuopion Yliopistollinen Sairaala
state: Pohjois-savo
city: Helsinki
country: Finland
facility: Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus)
state: Uusimaa
city: Turku
country: Finland
facility: Turku University Hospital
state: Varsinais-suomi
city: Nice
country: France
facility: Centre Hospitalier Universitaire de Nice - Hôpital l'Archet
state: Alpes-maritimes
city: Pessac
country: France
facility: CHU Bordeaux Haut-Leveque
state: Aquitaine
city: Vandoeuvre lès Nancy
country: France
facility: Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois
state: Lorraine
city: Dunkirk
country: France
facility: Centre Hospitalier de Dunkerque
state: Nord-pas-de-calais
city: Nantes
country: France
facility: Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
state: Pays-de-la-loire
city: Cergy Pontoise
country: France
facility: Hôpital NOVO
state: Val-d'oise
city: Pontoise
country: France
facility: Hôpital NOVO
state: Val-d'oise
city: Créteil
country: France
facility: Henri Mondor Hospital
state: Val-de-marne
city: La Roche-sur-Yon
country: France
facility: CHD Vendee
state: Vendée
city: Bayonne
country: France
facility: Centre Hospitalier de la Côte Basque
city: Le Mans
country: France
facility: Centre Hospitalier du Mans
city: Paris
country: France
facility: Hôpital Universitaire Necker Enfants Malades
city: Paris
country: France
facility: Hopitaux Universitaires Paris Centre-Hopital Cochin
city: Quimper
country: France
facility: Centre Hospitalier de Cornouaille
city: Tours
country: France
facility: Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau
city: Vannes
country: France
facility: Centre Hospitalier Bretagne Atlantique
city: Vannes
country: France
facility: Centre Hospitalier Bretagne Atlantique
city: Freiburg
country: Germany
facility: Universitaetsklinikum Freiburg
state: Baden-württemberg
city: Stuttgart
country: Germany
facility: Robert Bosch Krankenhaus GmbH
state: Baden-württemberg
city: Ulm
country: Germany
facility: Universitaetsklinikum Ulm
state: Baden-württemberg
city: Nürnberg
country: Germany
facility: Klinikum Nürnberg Nord
state: Bayern
city: Jena
country: Germany
facility: Universitätsklinikum Jena
state: Thüringen
city: Berlin
country: Germany
facility: Vivantes Klinikum Am Urban
city: Berlin
country: Germany
facility: Vivantes Klinikum Am Urban
city: Cottbus
country: Germany
facility: Medizinische Universität Lausitz - Carl Thiem
city: Hamburg
country: Germany
facility: Asklepios Altona
city: Hamm
country: Germany
facility: St. Barbara-Klinik Hamm-Heessen
city: Speyer
country: Germany
facility: Diakonissen-Stiftungs-Krankenhaus Speyer
city: Alexandroupolis
country: Greece
facility: University Hospital of Alexandroupolis
state: Anatolikí Makedonía KAI Thráki
city: Athens
country: Greece
facility: Evangelismos General Hospital of Athens
state: Attikí
city: Athens
country: Greece
facility: Alexandra General Hospital of Athens
state: Attikí
city: Thessaloniki
country: Greece
facility: "Theagenio" Cancer Hospital of Thessaloniki
state: Kentrikí Makedonía
city: Thessaloniki
country: Greece
facility: G. Papanikolaou General Hospital
state: Thessaloníki
city: Ioannina
country: Greece
facility: University Hospital of Ioannina
state: Ípeiros
city: Petah-Tikva
country: Israel
facility: Rabin Medical Center
state: Hamerkaz
city: Ramat Gan
country: Israel
facility: Sheba Medical Center
state: Hamerkaz
city: Tel Aviv
country: Israel
facility: Sourasky Medical Center
state: Tell Abīb
city: Jerusalem
country: Israel
facility: Hadassah Medical Center
state: Yerushalayim
city: Meldola
country: Italy
facility: IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
state: Emilia-romagna
city: Milano
country: Italy
facility: P.O. San Carlo Borromeo- ASST SANTI PAOLO E CARLO
state: Lombardia
city: Ancona
country: Italy
facility: Azienda Ospedaliero Universitaria delle Marche
state: Marche
city: Legnano
country: Italy
facility: Azienda Socio Sanitaria Ovest milanese
state: Milano
city: Torino
country: Italy
facility: Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
state: Piemonte
city: Palermo
country: Italy
facility: A.O.U. Policlinico Paolo Giaccone
state: Sicilia
city: Firenze
country: Italy
facility: Azienda Ospedaliera Universitaria Careggi
state: Toscana
city: Bologna
country: Italy
facility: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
city: Milano
country: Italy
facility: Istituto Europeo di Oncologia IRCCS
city: Pescara
country: Italy
facility: Ospedale Civile dello Spirito Santo
city: Nagoya
country: Japan
facility: Nagoya City University Hospital
state: Aichi
city: Toyohashi
country: Japan
facility: Toyohashi Municipal Hospital
state: Aichi
city: Matsuyama
country: Japan
facility: Ehime Prefectural Central Hospital
state: Ehime
city: Ogaki
country: Japan
facility: Ogaki Municipal Hospital
state: Gifu
city: Maebashi
country: Japan
facility: Gunma University Hospital
state: Gunma
city: Shibukawa
country: Japan
facility: National Hospital Organization Shibukawa Medical Center
state: Gunma
city: Kobe
country: Japan
facility: Kobe City Medical Center General Hospital
state: Hyogo
city: Shiwa-gun Yahaba-cho
country: Japan
facility: Iwate Medical University Hospital
state: Iwate
city: Nagaizumi-cho
country: Japan
facility: Shizuoka Cancer Center
state: Shizuoka
city: Bunkyo-ku
country: Japan
facility: Nippon Medical School Hospital
state: Tokyo
city: Koto
country: Japan
facility: Japanese Foundation for Cancer Research
state: Tokyo
city: Kofu-shi
country: Japan
facility: Yamanashi Prefectural Central Hospital
state: Yamanashi
city: Kagoshima
country: Japan
facility: Kagoshima University Hospital
city: Kyoto
country: Japan
facility: University Hospital,Kyoto Prefectural University of Medicine
city: Okayama
country: Japan
facility: National Hospital Organization Okayama Medical Center
city: Okayama
country: Japan
facility: Okayama Rosai Hospital
city: Yamagata
country: Japan
facility: Yamagata University Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
state: Seoul-teukbyeolsi [seoul]
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
state: Seoul-teukbyeolsi [seoul]
city: Maastricht
country: Netherlands
facility: Maastricht UMC+
state: Limburg
city: Dordrecht
country: Netherlands
facility: Albert Schweitzer Ziekenhuis, locatie Dordwijk
state: Zuid-holland
city: Lørenskog
country: Norway
facility: Akershus Universitetssykehus
state: Akershus
city: Trondheim
country: Norway
facility: St. Olavs Hospital
state: Sør-trøndelag
city: Tønsberg
country: Norway
facility: Sykehuset i Vestfold
state: Vestfold
city: Oslo
country: Norway
facility: Oslo Universitetssykehus Ullevål
city: Badalona
country: Spain
facility: Institut Català d'Oncologia (ICO) - Badalona
state: Barcelona [barcelona]
city: Barcelona
country: Spain
facility: Cetir-Ascires
state: Barcelona [barcelona]
city: Terrassa
country: Spain
facility: Hospital Universitari Mutua Terrassa
state: Barcelona [barcelona]
city: Barcelona
country: Spain
facility: Hospital Clínic de Barcelona
state: Catalunya [cataluña]
city: Murcia
country: Spain
facility: Hospital General Universitario Morales Meseguer
state: Galicia [galicia]
city: Girona
country: Spain
facility: Institut Català d'Oncologia (ICO) - Girona
state: Girona [gerona]
city: Madrid
country: Spain
facility: Hospital Universitario Infanta Leonor
state: Madrid, Comunidad DE
city: València
country: Spain
facility: ASCIRES ECG Médica S.L
state: Valenciana, Comunitat
city: Madrid
country: Spain
facility: Hospital General Universitario Gregorio Marañon
city: Madrid
country: Spain
facility: Hospital Universitario HM Sanchinarro
city: Málaga
country: Spain
facility: H.R.U Málaga - Hospital General
city: Salamanca
country: Spain
facility: Centro de Diagnóstico y Resonancia Magnética
city: Salamanca
country: Spain
facility: Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
city: València
country: Spain
facility: Hospital Universitari i Politecnic La Fe
city: Falun
country: Sweden
facility: Falu Lasarett
city: Örebro
country: Sweden
facility: Universitetssjukhuset Örebro
state: Örebro LÄN [se-18]
city: Taichung
country: Taiwan
facility: China Medical University Hospital
city: Bournemouth
country: United Kingdom
facility: Royal Bournemouth Hospital
state: Dorset
city: Poole
country: United Kingdom
facility: Poole Hospital
state: Dorset
city: Eastbourne
country: United Kingdom
facility: Eastbourne District General Hospital
state: EAST Sussex
city: Birmingham
country: United Kingdom
facility: Queen Elizabeth Hospital Birmingham
state: England
city: Maidstone
country: United Kingdom
facility: Maidstone Hospital
state: Kent
city: London
country: United Kingdom
facility: St Bartholomew's Hospital
state: London, CITY OF
city: London
country: United Kingdom
facility: Guy's & St Thomas' NHS Foundation Trust
state: London, CITY OF
city: London
country: United Kingdom
facility: King's College Hospital
state: London, CITY OF
city: London
country: United Kingdom
facility: Hammersmith Hospital
state: London, CITY OF
city: Oxford
country: United Kingdom
facility: Churchill Hospital
state: Oxfordshire
city: Stoke-on-Trent
country: United Kingdom
facility: Royal Stoke University Hospital
state: Staffordshire
city: London
country: United Kingdom
facility: Royal Marsden Hospital (Sutton)
state: Sutton
city: Canterbury
country: United Kingdom
facility: Kent and Canterbury Hospital
city: Wolverhampton
country: United Kingdom
facility: New Cross Hospital
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: